NCODA and Florida Cancer Specialists & Research Institute Announce New Oncology Stakeholder Education Exchange Program

Published: Aug. 16, 2022 at 10:00 AM EDT

CAZENOVIA, N.Y., Aug. 16, 2022 /PRNewswire/ -- New cancer treatment therapies, technologies and innovations continue to be discovered and approved for use at a rapid pace, creating an education challenge for physicians and other healthcare professionals within the complex oncology landscape. Working collaboratively with Florida Cancer Specialists & Research Institute, LLC (FCS), NCODA, Inc. developed a more efficient way for healthcare professionals to expand their knowledge and share feedback about ongoing advancements. FCS, the Florida oncology practice, will be the first to utilize this new program, which offers focused education for governance-level Board members, disease-state experts and generalists.

NCODA
NCODA(PRNewswire)
Rxchange will greatly enhance the two-way flow of information in an environment of rapid and unprecedented developments.

The virtual learning platform replaces traditional methods that can be cumbersome and time-consuming for physicians and their medical practice teams. On NCODA's unique platform, Rxchange, the latest updates and detailed information will be available in real-time and can be accessed quickly, at the user's convenience.

"As a patient-centered organization that works collaboratively with all stakeholders to enhance oncology care, NCODA is thrilled to bring a new and innovative program to fruition," says Michael Reff, RPh, MBA, NCODA Founder and Executive Director. "By working with the team at FCS, we are providing a smart-solution to an industry-wide challenge that will soon be available to all NCODA member practices." NCODA's 5,000+ membership base includes representation from over 900 practices throughout the U.S. and Canada.

Lucio Gordan, MD, FCS Chief Medical Officer for Therapeutics and Analytics, said, "Organizing the education and information exchange between providers and other health care stakeholders has been long overdue. Rxchange will greatly enhance the two-way flow of information in an environment of rapid and unprecedented developments in cancer care and help to enhance overall patient care."

About NCODA:

NCODA is a leading non-profit organization dedicated to empowering medically-integrated oncology practices to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards, and best practices. For more information about NCODA visit www.ncoda.org or follow @NCODA on LinkedIn.

For More Information, Contact:
Katie Edmiston, Marketing Manager 
(813) 843-1629
Katie.Edmiston@ncoda.org

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)

Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in prestigious medical schools and research institutes, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.

Founded in 1984, Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.

*Prior to approval

For More Information, Contact: 
Michelle Robey, Vice President of Marketing 
Michelle.Robey@FLCancer.com
(813) 767-9398

Jen Bradley, Director of Corporate Communications
(847) 280.1740 
Jen.Bradley@FLCancer.com

View original content to download multimedia:

SOURCE NCODA

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.